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Introduction {#cam4678-sec-0001}
============

Obesity defined in terms of body mass index (BMI) is a possible factor affecting the prognosis of patients with breast cancer. A previous meta‐analysis including 43 studies showed that obesity was associated with higher risk of all‐cause or breast cancer--specific death among pre‐ and postmenopausal women [1](#cam4678-bib-0001){ref-type="ref"}. A more recent large‐scale meta‐analysis of 82 studies conducted by the World Cancer Research Fund and American Institute for Cancer Research (WCRF/AICR) also showed that obese patients had poorer overall and breast cancer survival, for both pre‐ and postmenopausal patients, and that being underweight was not associated with breast cancer survival, although the latter included only 10 studies [2](#cam4678-bib-0002){ref-type="ref"}.

It has been suggested that associations between BMI and outcome in Asians may differ from those in Europe [3](#cam4678-bib-0003){ref-type="ref"}. A large‐scale study from Korea including 24,698 breast cancer patients demonstrated significantly lower overall and breast cancer--specific survival and a higher risk of recurrence in patients who were underweight than in those of normal weight, although no conclusion was drawn with regard to any association between overweight/obesity and breast cancer recurrence or death [4](#cam4678-bib-0004){ref-type="ref"}. A recent study from Japan suggested that both higher BMI and lower BMI are associated with an increased risk of mortality among breast cancer patients [5](#cam4678-bib-0005){ref-type="ref"}. However, the associations between being obese or underweight and survival among breast cancer patients have not been adequately assessed in Asian countries; previous meta‐analyses of Asian patients included only two [1](#cam4678-bib-0001){ref-type="ref"} and seven [2](#cam4678-bib-0002){ref-type="ref"} studies, respectively.

There is biological evidence that breast cancer is a heterogeneous disease [6](#cam4678-bib-0006){ref-type="ref"}, [7](#cam4678-bib-0007){ref-type="ref"}. There is considerable heterogeneity of breast cancer subtypes, each showing a distinct gene‐expression profile [6](#cam4678-bib-0006){ref-type="ref"}, [8](#cam4678-bib-0008){ref-type="ref"}. Biological heterogeneity defined by combined estrogen/progesterone receptor (ER/PR) and human epidermal growth factor receptor 2 (HER2) status may imply important differences in tumor etiology and prognosis [9](#cam4678-bib-0009){ref-type="ref"}. Thus, assessment of associations between BMI and breast cancer prognosis according to tumor subtypes defined by ER/PR/HER2 may shed further light on this relationship. In fact, several studies have already investigated the effects of tumor subtype defined by ER/PR status [10](#cam4678-bib-0010){ref-type="ref"}, [11](#cam4678-bib-0011){ref-type="ref"}, [12](#cam4678-bib-0012){ref-type="ref"}. A recent meta‐analysis of 21 studies, including the ER/PR status of breast cancer and menopausal status, showed that obesity impacted negatively on both overall and breast cancer survival irrespective of ER/PR and menopausal status [13](#cam4678-bib-0013){ref-type="ref"}. However, few studies have addressed the association between obesity and survival of breast cancer patients in terms of ER/PR/HER2 status [14](#cam4678-bib-0014){ref-type="ref"}, [15](#cam4678-bib-0015){ref-type="ref"}.

In this study, we investigated the relationship between BMI and the risk of all‐cause death and breast cancer--specific death among breast cancer patients in terms of menopausal status and also tumor subtype using a nationwide database in Japan.

Materials and Methods {#cam4678-sec-0002}
=====================

Study subjects, database, and clinical information {#cam4678-sec-0003}
--------------------------------------------------

The Japanese Breast Cancer Society (JBCS) has maintained the Breast Cancer Registry (BCR) supported by the Public Health Research Foundation (Tokyo). Affiliated institutes have voluntarily provided the BCR with data on newly diagnosed primary breast cancer cases through a web‐based system since 2004 [16](#cam4678-bib-0016){ref-type="ref"}. The National Clinical Database (NCD) in Japan, which was launched in 2010, is a nationwide prospective web‐based registry linked to the surgical board certification system. Detailed information about the NCD has been published previously [17](#cam4678-bib-0017){ref-type="ref"}, [18](#cam4678-bib-0018){ref-type="ref"}. In brief, the NCD systematically collects accurate data in order to develop a standardized database for improvement of quality and evaluation of healthcare quality from the standpoint of structure, process, and outcome [17](#cam4678-bib-0017){ref-type="ref"}. Detailed information on cancers, such as gastrointestinal, liver, pancreas, thyroid, and breast cancer, is also collected [19](#cam4678-bib-0019){ref-type="ref"}. The NCD contains \>1.2 million surgical cases collected up to 2011, and approximately 4000 institutions have been participating. The NCD continuously communicates with hospital personnel responsible for data collection through the NCD web‐based data management system, and also consistently performs random site visits to validate the submitted data. Between 2004 and 2011, 238,840 cases were transferred from the JBCS to the NCD for creation of the National Clinical Database---Breast Cancer Registry (NCD‐BCR). For our present study, we used NCD‐BCR data for 53,670 patients who had been newly diagnosed and registered as having breast cancer at 388 institutions between 2004 and 2006 and who were requested to attend for initial follow up at around 8 years after initial diagnosis. An estimate of newly diagnosed female breast cancer cases between 2004 and 2006 is 155,027 [20](#cam4678-bib-0020){ref-type="ref"}. Newly diagnosed breast cancer cases captured in this registry are 34.6%. Finally, 25,898 patients from 170 institutions were followed up.

Information on patients covering age, sex, height and weight, place of residence, detection method, family history of breast cancer, menopausal status, tumor characteristics, TNM classification, and treatment (chemotherapy, endocrine therapy, radiation therapy) was obtained from the NCD‐BCR. The TNM classification and histological classification were registered according to the UICC staging [21](#cam4678-bib-0021){ref-type="ref"} and WHO classification systems, [22](#cam4678-bib-0022){ref-type="ref"} respectively. Patients who were male (*n* = 231) or of unknown sex (*n* = 1), or who were at stage 0 (*n* = 5546) or IV (*n* = 1355) or unknown stage (*n* = 1349) were excluded, leaving a total of 45,188 patients. Information on ER/PR/HER2 was also obtained from the NCD‐BCR. ER/PR positivity was diagnosed if at least 1% of nuclei in the tumor were immunohistochemically positive for ER or PR. HER2 overexpression was defined as an immunohistochemical score of 3 +  and/or a positive FISH result. Cases were categorized into four subtypes on the basis of their status: luminal A (ER+/PR+/HER2−); luminal B (ER+/PR−/HER2− or ER+/HER2 +); HER2− overexpressing (ER−/PR−/HER2 + ); and triple negative (ER−/PR−/HER2−) [23](#cam4678-bib-0023){ref-type="ref"}.

Ascertainment of exposures and follow up {#cam4678-sec-0004}
----------------------------------------

Body mass index was calculated as weight divided by the square of height (kg/m^2^). Patients whose height or body weight was unknown (*n* = 2582) were excluded, as were those whose age (*n* = 206) and place of residence (*n* = 10) were unknown, leaving a total of 42,390 patients. We categorized BMI into a five‐level variable with reference to the WHO criteria, [24](#cam4678-bib-0024){ref-type="ref"} using a median value of 21.8 between 18.5 and 25.0: \<18.5 (underweight), ≥18.5--\<21.8 (reference), ≥21.8--\<25.0, ≥25.0--\<30.0 (overweight), and ≥30 (obese).

Figure [1](#cam4678-fig-0001){ref-type="fig"} shows a flow diagram of this study. Information on the date of follow up and status (alive, death from breast cancer, death due to causes other than breast cancer, and death due to unknown causes) and the date of recurrence and status (with or without recurrence) were obtained from the NCD‐BCR. During the study period, 20,090 (47.4%) patients were followed up.

![Study flow.](CAM4-5-1328-g001){#cam4678-fig-0001}

Statistical analysis {#cam4678-sec-0005}
--------------------

The endpoint of our analysis was all‐cause death, breast cancer--specific death, and recurrence. Recurrence included local (conserved breast, chest wall, axillary lymph nodes, and regional lymph nodes) and distant (lung, liver, bone, brain, distant lymph nodes, pleura, and others) metastasis. Survival time was calculated for each patient from the date of first treatment to the date of death, recurrence, or the end of follow up. We used date of first treatment instead of date of diagnosis because the NCD‐BCR does not have date of diagnosis.

The Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all‐cause death, breast cancer--specific death, and recurrence in relation to BMI [25](#cam4678-bib-0025){ref-type="ref"}. Dose--response relationships were tested by treating each exposure category as a continuous variable and were employed in the Cox model for BMI ≥18.5 because we expected the overall relationship of BMI to each endpoint to be U shaped rather than linear (i.e., we expected patients with BMI \<18.5 have higher mortality than the reference category). To evaluate a potential non‐linear relationship between BMI and each endpoint, we applied cubic splines with three knots in settled percentiles (10%, 50%, and 90%) of the distribution to model the possible association [26](#cam4678-bib-0026){ref-type="ref"}.

We considered the following variables to be potential confounders: age, place of residence (eastern Japan, western Japan), detection method (self‐detection, screening with symptoms, screening without symptoms, others), family history of breast cancer (no, yes), tumor stage \[Stage I, Stage II (IIA/IIB), Stage III (IIIA/IIIB/IIIC)\], chemotherapy (no, yes), endocrine therapy (no, yes), radiation therapy (no, yes, unknown), tumor subtype (luminal A, luminal B, HER2, triple negative, others), menopausal status (premenopausal, postmenopausal, unknown), and registration year (2004, 2005, 2006).

Separate analyses were conducted after dividing the patients according to menopausal status and tumor subtype, along with analysis of the patients overall. Menopause was defined as the cessation of menstrual periods for more than 1 year. Menopause resulting from surgery was defined as unknown menopausal status. To evaluate heterogeneity of the associations between BMI and each endpoint across tumor subtypes (Luminal B vs. Luminal A/ HER2− overexpressing/triple negative), interaction terms (BMI \* tumor subtypes) were tested.

Results were regarded as significant if the two‐sided *P* values were \<0.05. All statistical analyses were performed using the SAS 9.4 (SAS Institute, Cary, NC).

Results {#cam4678-sec-0006}
=======

The patient characteristics are shown in Table [1](#cam4678-tbl-0001){ref-type="table-wrap"}. During a median follow‐up period of 6.7 years, 1418 all‐cause deaths, 937 breast cancer--specific deaths, and 2433 recurrences were observed. Obese patients were more likely to have an advanced stage of breast cancer, a luminal A tumor, or to have undergone endocrine therapy. Underweight patients were more likely to have self‐detected tumors, and less likely to have undergone chemotherapy.

###### 

Patient characteristics

                                               BMI                                                                                
  --------------------------------- ---------- ------ -------- ------ --------- ------ --------- ------ --------- ------ -------- ------
  All‐cause death                   1418       7.1    138      8.8    414       6.1    476       7.0    298       7.4    92       10.3
  Breast cancer--specific death     937        4.7    73       4.7    287       4.2    323       4.8    191       4.8    63       7.0
  Recurrence                        2433       12.1   193      12.4   796       11.7   839       11.7   478       11.9   127      14.2
  Age (year)                                                                                                                      
  Mean (SD)                         57.3       12.8   54.8     14.7   54.0      12.9   58.6      12.1   60.9      11.9   59.7     11.9
  Median                            57.0              53.0            53.0             58.0             61.0             60.0     
  Follow up                                                                                                                       
  Median                            6.7               6.5             6.7              6.7              6.7              6.6      
  Person years                      119873.4          8875.8          40967.5          40681.3          24062.4          5286.3   
  Living place                                                                                                                    
  Eastern Japan                     9598       47.8   737      47.2   3247      47.5   3260      48.1   1917      47.8   437      48.7
  Western Japan                     10,492     52.2   824      52.8   3586      52.5   3524      52.0   2098      52.3   460      51.3
  Detection method                                                                                                                
  Self--detection                   14,736     73.4   1219     78.1   4988      73.0   4885      72.0   2948      73.4   696      77.6
  Screening with symptom            1203       6.0    81       5.2    441       6.5    402       5.9    235       5.9    44       4.9
  Screening without symptom         3131       15.6   175      11.2   1092      16.0   1130      16.7   625       15.6   109      12.2
  Others                            1020       5.1    86       5.5    312       4.6    367       5.4    207       5.2    48       5.4
  Family history of breast cancer                                                                                                 
  No                                17,078     85.0   1337     85.7   5827      85.3   5762      84.9   3392      84.5   760      84.7
  Yes                               1761       8.8    132      8.5    589       8.6    604       8.9    364       9.1    72       8.0
  Missing                           1251       6.2    92       5.9    417       6.1    418       6.2    259       6.5    65       7.3
  Tumor stage                                                                                                                     
  Stage I                           8304       41.3   725      46.4   3075      45.0   2765      40.8   1473      36.7   266      29.7
  Stage II (IIA/IIB)                9841       49.0   662      42.4   3186      46.6   3376      49.8   2102      52.4   515      57.4
  Stage III (IIIA/IIIB/IIIC)        1945       9.7    174      11.2   572       8.4    643       9.5    440       11.0   116      12.9
  Treatments                                                                                                                      
  Chemotherapy                                                                                                                    
  No                                10,638     53.0   889      57.0   3567      52.2   3557      52.4   2154      53.7   471      52.5
  Yes                               9452       47.1   672      43.1   3266      47.8   3227      47.6   1861      46.4   426      47.5
  Endocrine therapy                                                                                                               
  No                                6524       32.5   539      34.5   2339      34.2   2194      32.3   1220      30.4   232      25.9
  Yes                               13,566     67.5   1022     65.5   4494      65.8   4590      67.7   2795      69.6   665      74.1
  Radiation therapy                                                                                                               
  No                                10,543     52.5   848      54.3   3408      49.9   3577      52.7   2236      55.7   474      52.8
  Yes                               9409       46.8   700      44.8   3381      49.5   3161      46.6   1751      43.6   416      46.4
  Unknown                           138        0.7    13       0.8    44        0.6    46        0.7    28        0.7    7        0.8
  Tumor subtypes                                                                                                                  
  Luminal A                         9850       49.0   732      46.9   3252      47.6   3272      48.2   2084      51.9   510      56.9
  Luminal B                         3988       19.9   327      21.0   1378      20.2   1383      20.4   754       18.8   146      16.3
  HER2                              1485       7.4    122      7.8    542       7.9    523       7.7    258       6.4    40       4.5
  Triple negative                   2993       14.9   227      14.5   1064      15.6   1028      15.2   556       13.9   118      13.2
  Others                            1774       8.8    153      9.8    597       8.7    578       8.5    363       9.0    83       9.3
  Menopausal status                                                                                                               
  Premenopausal                     6785       33.8   696      44.6   3065      44.9   1923      28.4   879       21.9   222      24.8
  Postmenopausal                    12576      62.6   814      52.2   3524      51.6   4611      68.0   2987      74.4   640      71.4
  Unknown (including surgery)       729        3.6    51       3.3    244       3.6    250       3.7    149       3.7    35       3.9
  Registered year                                                                                                                 
  2004                              6368       31.7   468      30.0   2157      31.6   2195      32.4   1302      32.4   246      27.4
  2005                              7199       35.8   561      35.9   2432      35.6   2428      35.8   1434      35.7   344      38.4
  2006                              6523       32.5   532      34.1   2244      32.8   2161      31.9   1279      31.9   307      34.2

BMI, body mass index.
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Table [2](#cam4678-tbl-0002){ref-type="table-wrap"} shows the association of BMI with each endpoint. Compared to patients with BMI ≥18.5--\<21.8, those with BMI ≥30.0 were shown to have a higher risk of all‐cause death (HR: 1.46; 95% CI: 1.16--1.83; *P* = 0.0012) and breast cancer--specific death (HR: 1.47; 95% CI: 1.11--1.93; *P* = 0.0065). A dose--response relationship was observed between BMI and all‐cause death (P~trend~ = 0.026). Stratification by menopausal status revealed that postmenopausal obese patients had a higher risk of all‐cause death (HR: 1.47; 95% CI: 1.13--1.92; *P* = 0.0045) and breast cancer--specific death (HR: 1.58; 95% CI: 1.13--2.20; *P* = 0.0072). For premenopausal women, our results showed that obesity was associated with non‐significant higher risks of all‐cause death (HR: 1.46; 95% CI: 0.91--2.35) and breast cancer--specific death (HR: 1.34; 95% CI: 0.79--2.27). Underweight patients had a higher risk of all‐cause death among patients as a whole (HR: 1.41; 95% CI: 1.16--1.71; *P* = 0.0005) and among postmenopausal patients (HR: 1.45; 95% CI: 1.15--1.84; *P* = 0.0018).

###### 

HR (95% CI) of each endpoint with BMI overall and by menopausal status

  BMI              Cases   Events   All‐cause death                                   Events        Recurrence                                        Events                                            Breast cancer--specific death                                                                                                         
  ---------------- ------- -------- ------------------------------------------------- ------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------ ----- ------ ------------- --------
  All                                                                                                                                                                                                                                                                                                                                         
  ≥30              897     92       1.46                                              1.16--1.83    0.0012                                            127                                               1.15                                              0.95--1.39                                        0.15   63    1.47   1.11--1.93    0.0065
  ≥25--\<30        4015    298      1.04                                              0.90--1.21    0.58                                              478                                               0.97                                              0.87--1.09                                        0.61   191   1.03   0.86--1.24    0.75
  ≥21.8--\<25      6784    476      1.02                                              0.90--1.17    0.74                                              839                                               1.02                                              0.93--1.13                                        0.68   323   1.03   0.88--1.21    0.72
  ≥18.5--\<21.8    6833    414      Reference[a](#cam4678-note-0004){ref-type="fn"}                 796                                               Reference[a](#cam4678-note-0004){ref-type="fn"}   287                                               Reference[a](#cam4678-note-0004){ref-type="fn"}                                     
  \<18.5           1561    138      1.41                                              1.16--1.71    0.0005                                            193                                               1.09                                              0.94--1.28                                        0.26   73    1.16   0.90--1.50    0.27
  *P* ~*trend*~                                                                                     0.026                                                                                                                                                                                                   0.6                               0.067
  Premenopausal                                                                                                                                                                                                                                                                                                                               
  ≥30              222     20       1.46                                              0.91--2.35    0.12                                              35                                                1.21                                              0.85--1.71                                        0.29   16    1.34   0.79--2.27    0.28
  ≥25--\<30        879     62       1.10                                              0.81 --1.49   0.54                                              121                                               1.00                                              0.81 --1.23                                       0.99   54    1.09   0.78 --1.50   0.63
  ≥21.8--\<25      1923    98       0.90                                              0.69--1.17    0.44                                              225                                               0.91                                              0.77--1.08                                        0.26   81    0.86   0.64--1.14    0.29
  ≥18.5--\<21.8    3065    140      Reference[b](#cam4678-note-0005){ref-type="fn"}   364           Reference[b](#cam4678-note-0005){ref-type="fn"}   122                                               Reference[b](#cam4678-note-0005){ref-type="fn"}                                                                                       
  \<18.5           696     32       1.08                                              0.74--1.59    0.69                                              72                                                0.86                                              0.67--1.11                                        0.24   23    0.91   0.58--1.43    0.68
  *P* ~*trend*~                                                                                     0.21                                                                                                                                                                                                    0.71                              0.39
  Postmenopausal                                                                                                                                                                                                                                                                                                                              
  ≥30              640     70       1.47                                              1.13--1.92    0.0045                                            88                                                1.15                                              0.92--1.46                                        0.23   46    1.58   1.13--2.20    0.0072
  ≥25--\<30        2987    228      1.01                                              0.84--1.20    0.95                                              335                                               0.96                                              0.83--1.11                                        0.55   131   1.02   0.80--1.28    0.9
  ≥21.8--\<25      4611    354      1.02                                              0.87--1.20    0.78                                              570                                               1.06                                              0.93--1.20                                        0.39   229   1.11   0.91--1.36    0.31
  ≥18.5--\<21.8    3524    264      Reference[b](#cam4678-note-0005){ref-type="fn"}   414           Reference[b](#cam4678-note-0005){ref-type="fn"}   156                                               Reference[b](#cam4678-note-0005){ref-type="fn"}                                                                                       
  \<18.5           814     97       1.45                                              1.15--1.84    0.0018                                            113                                               1.19                                              0.97--1.47                                        0.1    45    1.22   0.88--1.71    0.24
  *P* ~*trend*~                                                                                     0.11                                                                                                                                                                                                    0.82                              0.11

HR, hazard ratio; CI, confidence interval; BMI, body mass index.

Adjusted by age, living place, detection method, family history of breast cancer, tumor stage, radiation therapy, chemotherapy, endocrine therapy, tumor subtypes, menopausal status, and registered year.

Adjusted by age, living place, detection method, family history of breast cancer, tumor stage, radiation therapy, chemotherapy, endocrine therapy, tumor subtypes, and registered year.
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Table [3](#cam4678-tbl-0003){ref-type="table-wrap"} shows the association of BMI with recurrence and breast cancer--specific death according to tumor subtype. Compared to patients with BMI ≥18.5--\<21.8, those with BMI ≥30.0 were shown to have a higher risk of breast cancer--specific death (HR: 2.59; 95% CI: 1.51--4.43; *P* = 0.0006; P~heterogeneity~ of Luminal B vs. Triple negative = 0.016) among patients with luminal B tumor. A dose--response relationship was observed between BMI and breast cancer--specific death (P~trend~ = 0.017).

###### 

HR (95% CI) of each endpoint with BMI by tumor subtypes

  BMI                                                               Cases   Events   Recurrence         Events       Breast cancer--specific death                             
  ----------------------------------------------------------------- ------- -------- ------------------ ------------ ------------------------------- ----- ------ ------------ --------
  Luminal A                                                                                                                                                                    
  ≥30                                                               510     50       1.23               0.90--1.68   0.19                            17    1.64   0.93--2.90   0.087
  ≥25--\<30                                                         2084    173      1.07               0.87--1.31   0.53                            49    1.27   0.84--1.92   0.26
  ≥21.8--\<25                                                       3272    258      1.11               0.92--1.33   0.27                            56    1.05   0.71--1.56   0.81
  ≥18.5--\<21.8                                                     3252    221      1.00 (Reference)   46           1.00 (Reference)                                          
  \<18.5                                                            732     63       1.24               0.93--1.64   0.14                            15    1.39   0.77--2.49   0.27
  *P* ~*trend*~                                                                                                      0.25                                                      0.075
  Luminal B                                                                                                                                                                    
  ≥30                                                               146     26       1.16               0.77--1.75   0.49                            18    2.59   1.51--4.43   0.0006
  ≥25--\<30                                                         754     98       0.87               0.68--1.12   0.27                            38    1.14   0.75--1.74   0.54
  ≥21.8--\<25                                                       1383    196      1.01               0.83--1.24   0.9                             59    1.07   0.73--1.54   0.74
  ≥18.5--\<21.8                                                     1378    194      1.00 (Reference)   56           1.00 (Reference)                                          
  \<18.5                                                            327     41       0.97               0.70--1.37   0.88                            15    1.32   0.75--2.35   0.34
  *P* ~*trend*~                                                                                                      0.68                                                      0.017
  HER2                                                                                                                                                                         
  ≥30                                                               40      12       1.24               0.68--2.26   0.49                            7     1.53   0.68--3.42   0.3
  ≥25--\<30                                                         258     46       0.74               0.52--1.05   0.094                           13    0.43   0.23--0.80   0.0077
  ≥21.8--\<25                                                       523     112      0.93               0.72--1.22   0.61                            43    0.73   0.48--1.10   0.13
  ≥18.5--\<21.8                                                     542     114      1.00 (Reference)   50           1.00 (Reference)                                          
  \<18.5                                                            122     25       0.95               0.61--1.47   0.8                             12    0.99   0.52--1.89   0.98
  *P* ~*trend*~                                                                                                      0.32                                                      0.097
  Triple negative                                                                                                                                                              
  ≥30                                                               118     29       1.09               0.74--1.62   0.67                            18    1.11   0.67--1.84   0.68
  ≥25--\<30                                                         556     114      0.95               0.75--1.20   0.66                            72    1.03   0.77--1.39   0.84
  ≥21.8--\<25                                                       1028    230      1.08               0.89--1.31   0.44                            145   1.15   0.90--1.48   0.26
  ≥18.5--\<21.8                                                     1064    200      1.00 (Reference)   112          1.00 (Reference)                                          
  \<18.5                                                            227     50       1.15               0.84--1.57   0.39                            24    0.97   0.62--1.51   0.89
  *P* ~*trend*~                                                                                                      0.97                                                      0.65
  Luminal B versus Luminal A -- P~heterogeneity~ of trends          0.25                                             0.7                                                       
  Luminal B versus HER2 -- P~heterogeneity~ of trends               0.56                                             0.0062                                                    
  Luminal B versus Triple negative -- P~heterogeneity~ of trends    0.79                                             0.059                                                     
  Luminal B versus Luminal A -- P~heterogeneity~ of BMI ≥30         0.77                                             0.25                                                      
  Luminal B versus HER2 -- P~heterogeneity~ of BMI ≥30              0.86                                             0.29                                                      
  Luminal B versus Triple negative -- P~heterogeneity~ of BMI ≥30   0.82                                             0.016                                                     

Adjusted by age, living place, detection method, family history of breast cancer, tumor stage, radiation therapy, chemotherapy, endocrine therapy, menopausal status, and registered year.

HR, hazard ratio; CI, confidence interval; BMI, body mass index.
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Stratification by menopausal status among patients with luminal B tumor (Table [4](#cam4678-tbl-0004){ref-type="table-wrap"}) revealed that postmenopausal obese patients had a higher risk of breast cancer--specific death (HR: 3.24; 95% CI: 1.71--6.17; *P* = 0.0003). A dose--response relationship was observed between BMI and breast cancer--specific death (P~trend~ = 0.022).

###### 

HR (95% CI) of each endpoint with BMI by menopausal status among luminal B tumor

  BMI              Cases   Events   Recurrence   Events       Breast cancer--specific death                            
  ---------------- ------- -------- ------------ ------------ ------------------------------- ---- ------ ------------ --------
  Premenopausal                                                                                                        
  ≥30              30      8        1.41         0.67--3.01   0.37                            4    1.95   0.63--6.10   0.25
  ≥25--\<30        114     17       0.97         0.57--1.66   0.91                            7    1.07   0.45--2.55   0.87
  ≥21.8--\<25      283     42       0.93         0.63--1.37   0.73                            12   0.90   0.44--1.84   0.77
  ≥18.5--\<21.8    481     73       Reference    23           Reference                                                
  \<18.5           100     12       0.83         0.45--1.54   0.56                            3    0.74   0.22--2.49   0.62
  *P* ~*trend*~                                               0.67                                                     0.47
  Postmenopausal                                                                                                       
  ≥30              109     18       1.09         0.66--1.80   0.72                            14   3.24   1.71--6.17   0.0003
  ≥25--\<30        613     76       0.81         0.61--1.09   0.16                            29   1.19   0.71--1.99   0.5
  ≥21.8--\<25      1054    147      1.02         0.80--1.30   0.89                            46   1.27   0.80--2.02   0.31
  ≥18.5--\<21.8    847     118      Reference    31           Reference                                                
  \<18.5           215     27       0.95         0.63--1.45   0.81                            10   1.39   0.68--2.86   0.37
  *Ptrend*                                                    0.35                                                     0.022

HR, hazard ratio; CI, confidence interval; BMI, body mass index.

Adjusted by age, living place, detection method, family history of breast cancer, tumor stage, radiation therapy, chemotherapy, endocrine therapy, and registered year.

John Wiley & Sons, Ltd

Figure [2](#cam4678-fig-0002){ref-type="fig"} shows HR and the corresponding 95% CI of multivariate‐restricted cubic splines between BMI and each endpoint. A dose--response relationship was observed between BMI and all‐cause death, higher BMI and breast cancer--specific death (Fig. [2](#cam4678-fig-0002){ref-type="fig"}A and B) overall. Among postmenopausal patients a dose--response relationship was observed between BMI and all‐cause death, higher BMI and breast cancer--specific death (Fig. [2](#cam4678-fig-0002){ref-type="fig"}C and D). Among patients with luminal B tumor, a dose--response relationship was observed between higher BMI and breast cancer--specific death overall (Fig. [2](#cam4678-fig-0002){ref-type="fig"}E) and postmenopausal patients (Fig. [1](#cam4678-fig-0001){ref-type="fig"}F).

![HR (ln of HR) and the corresponding 95% confidence intervals (CIs), using multivariate restricted cubic splines between body mass index (BMI) and each endpoint: (A) all‐cause death for all, (B) breast cancer--specific death for all, (C) all‐cause death for postmenopausal, (D) breast cancer--specific death for postmenopausal, (E) breast cancer--specific death for all with luminal B tumor, and (F) breast cancer--specific death for postmenopausal with luminal B tumor. The solid line and dash lines indicate HR and 95% CI.](CAM4-5-1328-g002){#cam4678-fig-0002}

Discussion {#cam4678-sec-0007}
==========

Our present study demonstrated that being obese or underweight was associated with an increased risk of death overall, especially for postmenopausal patients. In terms of tumor subtype and menopausal status, obesity was associated with an increased risk of death in patients with luminal B tumor and in patients who were postmenopausal. The association between BMI and survival among breast cancer patients has not been adequately addressed in Asian countries [1](#cam4678-bib-0001){ref-type="ref"}, [2](#cam4678-bib-0002){ref-type="ref"}. Our study is therefore of importance in that a nationwide database in Japan has been analyzed for the first time in a prospective setting, involving a large number of breast cancer patients stratified according to tumor subtype and menopausal status.

A meta‐analysis including 213,075 breast cancer patients with 41,477 deaths (23,182 from breast cancer) reported that the relative risk (RR) of total mortality for obese patients was 1.41 (95% CI: 1.29--1.53) and that of breast cancer mortality was 1.35 (95% CI: 1.24--1.47) in comparison with patients of normal weight [2](#cam4678-bib-0002){ref-type="ref"}. That study also revealed that the RR of total mortality for obese patients was 1.75 (95% CI: 1.26--2.41) among those who were premenopausal and 1.34 (95% CI: 1.18--1.53) for those who were postmenopausal, whereas the RR of breast cancer mortality was 1.50 (95% CI: 1.13--2.00) for premenopausal women and 1.34 (95% CI: 1.21--1.48) for postmenopausal women in comparison with women of normal weight [2](#cam4678-bib-0002){ref-type="ref"}. Our present results are consistent with these, showing that obesity was associated with a higher risk of all‐cause death and breast cancer--specific death for the patients overall and for postmenopausal patients. For premenopausal women, our present results demonstrated that obesity was associated with a non‐significant higher risk of all‐cause death and breast cancer--specific death. One possible reason for this relationship may have been the slightly higher proportion of obese patients with advanced‐stage breast cancer. Therefore, we attempted to analyze the data for Stage I breast cancer alone. However, this yielded almost the same results (Table [5](#cam4678-tbl-0005){ref-type="table-wrap"}). We hypothesized a reason for a slightly higher proportion of obese patients with advanced‐stage cancer. This might be due to the development of more aggressive tumors rather than screening behavior. The proportion of TNBC, an aggressive type of tumor, in overweight or obese women was lower than others.

###### 

HR (95% CI) of each endpoint with BMI by Stage I or I + II overall and by menopausal status

                   Cases   Events   All‐cause death                                          Events        Recurrence                                               Events   Breast cancer--specific death                                                                             
  ---------------- ------- -------- -------------------------------------------------------- ------------- -------------------------------------------------------- -------- -------------------------------------------------------- ------------- -------- ----- ------ ------------ --------
  Stage I                                                                                                                                                                                                                                                                              
  All                                                                                                                                                                                                                                                                                  
  ≥30              266     17       2.85                                                     1.66--4.92    0.0002                                                   17       1.69                                                     1.02--2.81    0.041    7     3.38   1.46--7.83   0.0045
  ≥25--\<30        1473    52       1.30                                                     0.89--1.89    0.18                                                     76       1.14                                                     0.86--1.51    0.38     20    1.42   0.79--2.55   0.24
  ≥21.8--\<25      2765    79       1.17                                                     0.83--1.64    0.37                                                     140      1.10                                                     0.87--1.39    0.43     33    1.32   0.79--2.20   0.29
  ≥18.5--\<21.8    3075    62       1.00 (Reference)[a](#cam4678-note-0010){ref-type="fn"}   155           1.00 (Reference)[a](#cam4678-note-0010){ref-type="fn"}   28       1.00 (Reference)[a](#cam4678-note-0010){ref-type="fn"}                                                    
  \<18.5           725     27       1.90                                                     1.21--2.99    0.0056                                                   46       1.31                                                     0.94--1.82    0.11     8     1.36   0.62--3.00   0.44
  *P* ~*trend*~                                                                                            0.0026                                                                                                                                   0.081                              0.017
  Premenopausal                                                                                                                                                                                                                                                                        
  ≥30              59      1        3.69                                                     0.46--29.63   0.22                                                     0        --                                                       --            --       0     --     --           --
  ≥25--\<30        276     6        2.46                                                     0.89--6.76    0.082                                                    16       1.54                                                     0.89--2.68    0.13     4     2.60   0.75--9.04   0.13
  ≥21.8--\<25      765     13       2.25                                                     0.99--5.07    0.052                                                    38       1.25                                                     0.83 --1.86   0.29     10    2.85   1.07--7.60   0.037
  ≥18.5--\<21.8    1407    11       1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}   67            1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}   7        1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}                                                    
  \<18.5           344     2        0.75                                                     0.17--3.43    0.71                                                     19       1.10                                                     0.66--1.83    0.73     1     0.56   0.07--4.60   0.59
  *P* ~*trend*~                                                                                            0.034                                                                                                                                    0.51                               0.12
  Postmenopausal                                                                                                                                                                                                                                                                       
  ≥30              198     14       2.43                                                     1.33--4.44    0.0038                                                   16       2.16                                                     1.26--3.72    0.0052   6     3.12   1.23--7.91   0.017
  ≥25--\<30        1145    45       1.15                                                     0.77--1.74    0.5                                                      57       1.04                                                     0.74 --1.46   0.82     15    1.15   0.58--2.27   0.7
  ≥21.8--\<25      1906    64       1.03                                                     0.70--1.50    0.89                                                     96       1.05                                                     0.78 --1.42   0.74     22    1.03   0.55--1.93   0.92
  ≥18.5--\<21.8    1571    49       1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}   84            1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}   19       1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}                                                    
  \<18.5           354     22       1.85                                                     1.11--3.07    0.018                                                    23       1.29                                                     0.81 --2.04   0.29     5     1.29   0.48--3.48   0.61
  *P* ~*trend*~                                                                                            0.041                                                                                                                                    0.11                               0.14
  Stage I + II                                                                                                                                                                                                                                                                         
  All                                                                                                                                                                                                                                                                                  
  ≥30              781     63       1.69                                                     1.29--2.23    0.0002                                                   85       1.27                                                     1.01--1.60    0.039    39    1.83   1.29--2.60   0.0007
  ≥25--\<30        3575    194      1.04                                                     0.87--1.25    0.67                                                     332      1.03                                                     0.90--1.18    0.69     110   1.07   0.84--1.37   0.56
  ≥21.8--\<25      6141    340      1.10                                                     0.94--1.29    0.23                                                     622      1.10                                                     0.98--1.24    0.092    213   1.20   0.98--1.46   0.079
  ≥18.5--\<21.8    6261    283      1.00 (Reference)[a](#cam4678-note-0010){ref-type="fn"}   596           1.00 (Reference)[a](#cam4678-note-0010){ref-type="fn"}   181      1.00 (Reference)[a](#cam4678-note-0010){ref-type="fn"}                                                    
  \<18.5           1387    87       1.41                                                     1.11--1.80    0.0049                                                   138      1.10                                                     0.91--1.32    0.34     39    1.08   0.76--1.52   0.68
  *P* ~*trend*~                                                                                            0.014                                                                                                                                    0.11                               0.014
  Premenopausal                                                                                                                                                                                                                                                                        
  ≥30              190     10       1.71                                                     0.88--3.30    0.11                                                     20       1.17                                                     0.74--1.84    0.51     9     1.79   0.89--3.60   0.1
  ≥25-- \<30       766     37       1.47                                                     1.00--2.17    0.05                                                     81       1.15                                                     0.89--1.47    0.28     32    1.51   1.00--2.30   0.052
  ≥21.8--\<25      1735    61       1.11                                                     0.80--1.54    0.53                                                     166      1.04                                                     0.86--1.26    0.7      50    1.09   0.76--1.56   0.65
  ≥18.5--\<21.8    2844    89       1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}   276           1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}   76       1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}                                                    
  \<18.5           643     19       0.97                                                     0.59--1.59    0.9                                                      54       0.83                                                     0.62--1.11    0.2      11    0.65   0.35--1.23   0.19
  *P* ~*trend*~                                                                                            0.025                                                                                                                                    0.23                               0.025
  Postmenopausal                                                                                                                                                                                                                                                                       
  ≥30              558     51       1.66                                                     1.22--2.27    0.0014                                                   63       1.37                                                     1.04--1.80    0.024    29    1.90   1.25--2.88   0.0026
  ≥25--\<30        2677    153      0.96                                                     0.77--1.19    0.7                                                      238      1.00                                                     0.84--1.19    0.99     75    0.98   0.72--1.32   0.88
  ≥21.8--\<25      4172    260      1.07                                                     0.89--1.29    0.48                                                     421      1.12                                                     0.97--1.30    0.13     153   1.26   0.98--1.63   0.073
  ≥18.5--\<21.8    3191    186      1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}   306           1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}   98       1.00 (Reference)[b](#cam4678-note-0011){ref-type="fn"}                                                    
  \<18.5           697     62       1.44                                                     1.08--1.93    0.013                                                    79       1.26                                                     0.98--1.62    0.067    26    1.33   0.86--2.05   0.2
  *P* ~*trend*~                                                                                            0.14                                                                                                                                     0.23                               0.13

HR, hazard ratio; CI, confidence interval; BMI, body mass index.

Adjusted by age, living place, detection method, family history of breast cancer, radiation therapy, chemotherapy, endocrine therapy, tumor subtypes, menopausal status, and registered year.

Adjusted by age, living place, detection method, family history of breast cancer, radiation therapy, chemotherapy, endocrine therapy, tumor subtypes, and registered year.

John Wiley & Sons, Ltd

Our present study demonstrated that underweight patients had an increased risk of all‐cause death, among both the patients overall and those who were postmenopausal. A previous meta‐analysis of 10 studies had shown that being underweight had no association with breast cancer survival [2](#cam4678-bib-0002){ref-type="ref"}. Also a large study of Korean breast cancer patients had shown that underweight patients were at a significantly higher risk of all‐cause death (HR: 1.48; 95% CI: 1.15--1.90) [4](#cam4678-bib-0004){ref-type="ref"}. Underweight patients might have included undernourished patients, especially among postmenopausal women, as well as properly nourished, naturally lean patients. In patients showing chronic undernutrition, cytokine reactions and subsequent activation of the immune system are compromised [27](#cam4678-bib-0027){ref-type="ref"}. This may have partly contributed to the increased risk of all‐cause death among underweight, postmenopausal women. Another reason for the association between being underweight and the higher risk of all‐cause death might have been the slightly higher proportion of patients with advanced‐stage breast cancer. Therefore, we attempted to analyze the data by omitting cases of advanced breast cancer. However, this yielded almost the same results (Table [5](#cam4678-tbl-0005){ref-type="table-wrap"}).

A few studies have reported the association between BMI and survival of breast cancer patients with combined ER/PR/HER2 status [14](#cam4678-bib-0014){ref-type="ref"}, [15](#cam4678-bib-0015){ref-type="ref"}. One study found that a higher BMI was associated with shorter disease‐free survival in postmenopausal patients, but no independent effect of any specific subtype was observed [14](#cam4678-bib-0014){ref-type="ref"}. The other study showed that patients with ER--/HER2 + tumors showed significantly worse overall survival and that a higher proportion of obese patients had distant metastases [15](#cam4678-bib-0015){ref-type="ref"}. In our present study, an association of obesity with poorer outcome was seen in patients with luminal B tumors overall and among postmenopausal patients. Patients with luminal B tumors had a poorer prognosis than those with luminal A tumors [6](#cam4678-bib-0006){ref-type="ref"} and were usually recommended to undergo endocrine therapy and chemotherapy [23](#cam4678-bib-0023){ref-type="ref"}. Obese and older breast cancer patients tend to show poorer survival because of suboptimal chemotherapy resulting from comorbidities and chemotherapy dose reduction due to concerns about toxicity [28](#cam4678-bib-0028){ref-type="ref"}. Differences in trastuzumab treatment might modify the association of obesity with breast cancer survival in patients with HER2‐positive breast cancer. Among the patients receiving trastuzumab and chemotherapy, [29](#cam4678-bib-0029){ref-type="ref"} those who are obese might show poorer survival than normal weight patients because of more severe trastuzumab‐induced cardiotoxicity [30](#cam4678-bib-0030){ref-type="ref"}. Obesity is also associated with poorer survival after endocrine therapy in breast cancer patients [31](#cam4678-bib-0031){ref-type="ref"}. In postmenopausal obese patients, higher synthesis of peripheral estrogen in adipose tissue [32](#cam4678-bib-0032){ref-type="ref"}, [33](#cam4678-bib-0033){ref-type="ref"}, [34](#cam4678-bib-0034){ref-type="ref"} is the most likely mechanism responsible for the higher risk of breast cancer--specific death [35](#cam4678-bib-0035){ref-type="ref"}. A recent systematic review reported that obesity was associated with decreased efficacy of endocrine therapy in postmenopausal patients with hormone receptor‐positive tumors [36](#cam4678-bib-0036){ref-type="ref"}. Suboptimal endocrine therapy and chemotherapy might explain the poorer outcome of postmenopausal obese patients with luminal B tumors. Further studies will be needed to clarify these associations.

There was increasing evidence that a specific BMI reflects a higher percentage of body fat among Asian populations at a given BMI than do white or European [37](#cam4678-bib-0037){ref-type="ref"}. A previous study in Japan suggested that BMI ≥25 adequately specifies complication, [38](#cam4678-bib-0038){ref-type="ref"} where the prevalence and degree of obesity remain mild [39](#cam4678-bib-0039){ref-type="ref"}. A WHO Expert Consultation panel in 2002 proposed BMI cut‐off points for Asians for policy and intervention strategies; \<18.5 (underweight), ≥18.5--\<23 (reference), ≥23--\<27.5 (increased risk), and ≥27.5 (high risk). Table [6](#cam4678-tbl-0006){ref-type="table-wrap"} shows the association of BMI with each endpoint by this cut offs overall and by menopausal status. Those with BMI ≥27.5 were not shown to have a higher risk of all‐cause death, but shown to have a higher risk of breast cancer--specific death (HR: 1.24; 95% CI: 1.01--1.52; *P* = 0.0038). A dose--response relationship was observed between BMI and breast cancer--specific death (P~trend~ = 0.048). Postmenopausal patients with BMI ≥27.5 did not have a higher risk of all‐cause death, but have a higher risk of breast cancer--specific death (HR: 1.30; 95% CI: 1.02--1.65; *P* = 0.035). A dose--response relationship was observed between BMI and breast cancer--specific death (P~trend~ = 0.04). There might be some kind of metabolic reserve which is not protective at high levels of obesity for all‐cause death. BMI cut‐off points for Asians might not be useful for policy, and intervention strategies in this cohort as BMI of ≥18.5--\<25 were already recommended to maintain a healthy condition [40](#cam4678-bib-0040){ref-type="ref"}. The WHO Expert Consultation also recommended to use all categories for reporting purposes with a view to facilitating international comparisons whenever possible [37](#cam4678-bib-0037){ref-type="ref"}.

###### 

HR (95% CI) of each endpoint with BMI cut offs for Asian populations overall and by menopausal status

  BMI              Cases   Events   All‐cause death                                          Events       Recurrence                                               Events   Breast cancer--specific death                                                                           
  ---------------- ------- -------- -------------------------------------------------------- ------------ -------------------------------------------------------- -------- -------------------------------------------------------- ------------- ------ ----- ------ ------------ -------
  All                                                                                                                                                                                                                                                                               
  ≥27.5            2130    179      1.16                                                     0.98--1.37   0.09                                                     282      1.05                                                     0.92--1.20    0.46   125   1.24   1.01--1.52   0.038
  ≥23--\<27.5      6685    485      1.04                                                     0.92--1.17   0.55                                                     797      0.97                                                     0.88--1.06    0.46   320   1.05   0.91--1.22   0.49
  ≥18.5--\<23      9714    616      1.00 (Reference)[a](#cam4678-note-0013){ref-type="fn"}   1161         1.00 (Reference)[a](#cam4678-note-0013){ref-type="fn"}   419      1.00 (Reference)[a](#cam4678-note-0013){ref-type="fn"}                                                  
  \<18.5           1561    138      1.40                                                     1.16--1.69   0.0004                                                   193      1.08                                                     0.93--1.26    0.33   73    1.17   0.91--1.50   0.23
  *P* ~*trend*~                                                                                           0.11                                                                                                                                     0.77                             0.048
  Premenopausal                                                                                                                                                                                                                                                                     
  ≥27.5            474     36       1.20                                                     0.84--1.73   0.32                                                     68       1.06                                                     0.82--1.37    0.67   31    1.19   0.80--1.76   0.39
  ≥23--\<27.5      1669    101      1.03                                                     0.81--1.32   0.81                                                     209      0.94                                                     0.80--1.11    0.48   84    0.99   0.76--1.29   0.93
  ≥18.5--\<23      3946    183      1.00 (Reference)[b](#cam4678-note-0014){ref-type="fn"}   468          1.00 (Reference)[b](#cam4678-note-0014){ref-type="fn"}   158      1.00 (Reference)[b](#cam4678-note-0014){ref-type="fn"}                                                  
  \<18.5           696     32       1.11                                                     0.76--1.62   0.6                                                      72       0.87                                                     0.68--1.11    0.26   23    0.94   0.60--1.46   0.78
  *P* ~*trend*~                                                                                           0.35                                                                                                                                     0.94                             0.5
  Postmenopausal                                                                                                                                                                                                                                                                    
  ≥27.5            1575    140      1.16                                                     0.96--1.41   0.13                                                     204      1.06                                                     0.91 --1.25   0.45   92    1.30   1.02--1.65   0.035
  ≥23--\<27.5      4753    364      1.03                                                     0.89--1.18   0.74                                                     545      0.97                                                     0.86 --1.08   0.54   224   1.09   0.91--1.31   0.36
  ≥18.5--\<23      5434    412      1.00 (Reference)[b](#cam4678-note-0014){ref-type="fn"}   658          1.00 (Reference)[b](#cam4678-note-0014){ref-type="fn"}   246      1.00 (Reference)[b](#cam4678-note-0014){ref-type="fn"}                                                  
  \<18.5           814     97       1.45                                                     1.16--1.81   0.0011                                                   113      1.16                                                     0.95 --1.42   0.14   45    1.22   0.89--1.67   0.23
  *P* ~*trend*~                                                                                           0.19                                                                                                                                     0.71                             0.04

HR, hazard ratio; CI, confidence interval; BMI, body mass index.

Adjusted by age, living place, detection method, family history of breast cancer, tumor stage, radiation therapy, chemotherapy, endocrine therapy, tumor subtypes, menopausal status, and registered year.

Adjusted by age, living place, detection method, family history of breast cancer, tumor stage, radiation therapy, chemotherapy, endocrine therapy, tumor subtypes, and registered year.
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Several limitations of our study should be considered. First, due to the timing of weight measurement, exposure might have been misclassified to some degree. This might be important, as there are some concerns regarding the adverse prognostic implications of a change in BMI after diagnosis of breast cancer [41](#cam4678-bib-0041){ref-type="ref"}. A recent review describing the association between weight change and breast cancer prognosis concluded that the existing data are conflicting [42](#cam4678-bib-0042){ref-type="ref"}. A meta‐analysis found no significant difference between the timing of BMI measurement and breast cancer outcome [2](#cam4678-bib-0002){ref-type="ref"}. Second, there was a relatively low rate of follow up during the study period. Follow up was requested from the NCD and performed by each of the institutions participating in the NCD‐BCR, but was not mandatory. We compared the background of patients who were followed up and those who were not, but found no apparent difference between the two groups (Table S1). The results of our study were almost consistent with those of the previous large‐scale meta‐analysis of qualified studies conducted by the WCRF/AICR [2](#cam4678-bib-0002){ref-type="ref"}. Third, our study included no information on comorbidity. Both obese and underweight patients are thought to have a higher risk of comorbid conditions. Fourth, Japan is ethnically homogeneous, and the patients included in our study were all female patients living in Japan. Therefore, the external validity of our results will need to be considered cautiously. Fifth, our study included no information on body composition. The relation between BMI and lean or fat mass may differ between people, but BMI cannot distinguish lean mass from body fat distribution. There have been several studies investigating between body fatness and survival in breast cancer patients. Two studies found negative association between body fat and survival, [43](#cam4678-bib-0043){ref-type="ref"}, [44](#cam4678-bib-0044){ref-type="ref"} but others did not [45](#cam4678-bib-0045){ref-type="ref"}, [46](#cam4678-bib-0046){ref-type="ref"}. Sixth, we do not have key confounders: smoking, alcohol, and physical activity. This might cause bias. Smoking rate in 2015 was 10.6% and alcohol consumption rate in 2005 was 8.0% [47](#cam4678-bib-0047){ref-type="ref"} among Japanese women, which were lower than other countries. Recent large studies from Korea also do not have items of smoking, alcohol, and physical activity [4](#cam4678-bib-0004){ref-type="ref"}, [48](#cam4678-bib-0048){ref-type="ref"}.

Among breast cancer patients living in Japan, being obese or underweight is associated with a higher risk of all‐cause death, especially in postmenopausal patients. There is some suggestion that postmenopausal obese patients with luminal B tumors have a poorer prognosis. A few studies have addressed the association between underweight and outcome of breast cancer patients in terms of ER/PR/HER2 status [1](#cam4678-bib-0001){ref-type="ref"}, [2](#cam4678-bib-0002){ref-type="ref"}, [14](#cam4678-bib-0014){ref-type="ref"}, [15](#cam4678-bib-0015){ref-type="ref"}. As higher and lower BMI are directly related to mortality, [49](#cam4678-bib-0049){ref-type="ref"} it is important for breast cancer patients to maintain an appropriate body weight for height.
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